Longevity is no longer confined to labs. It's a full-blown lifestyle industry projected to hit $40B + by 2030. Americans are spending up to $25K/year on longevity clinics. But most of these interventions are off-label, unregulated, and no real data.

While the culture is buying in, the science is left behind. Why? Because aging isn't classified as a disease. Yet.

Cracks are forming and regulators are waking up: Countries like Germany and Japan are debating reclassifying aging as a treatable target.

Real longevity science is happening now. IP tokens give you access to that research - early, transparently, and communally governed.